89809-65-4 Usage
Description
Methyl 6-Cyanopyridine-3-carboxylate is a cyanopyridine derivative with the chemical formula C8H6N2O3. It is a white to light yellow solid that is soluble in organic solvents such as ethanol and acetone. Methyl 6-Cyanopyridine-3-carboxylate is commonly used as an intermediate in the synthesis of pharmaceuticals, dyes, and agrochemicals, and has potential applications in medicinal chemistry, material science, and organic synthesis. Due to its potential health and environmental hazards, it is important to handle this compound with caution.
Uses
Used in Pharmaceutical Industry:
Methyl 6-Cyanopyridine-3-carboxylate is used as an intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic properties.
Used in Dye Industry:
In the dye industry, Methyl 6-Cyanopyridine-3-carboxylate is used as a chemical intermediate to produce a range of dyes, contributing to the coloration and properties of various products.
Used in Agrochemical Industry:
Methyl 6-Cyanopyridine-3-carboxylate serves as an intermediate in the production of agrochemicals, aiding in the development of compounds that can enhance crop protection and yield.
Used in Medicinal Chemistry:
Methyl 6-Cyanopyridine-3-carboxylate is utilized in medicinal chemistry for its potential role in the synthesis of new pharmaceutical agents, targeting various diseases and conditions.
Used in Material Science:
In material science, Methyl 6-Cyanopyridine-3-carboxylate is used in the development of new materials with specific properties, such as conductivity or stability, for various applications.
Used in Organic Synthesis:
Methyl 6-Cyanopyridine-3-carboxylate is employed in organic synthesis as a versatile building block for the creation of a wide range of organic compounds with diverse applications.
Check Digit Verification of cas no
The CAS Registry Mumber 89809-65-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,9,8,0 and 9 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 89809-65:
(7*8)+(6*9)+(5*8)+(4*0)+(3*9)+(2*6)+(1*5)=194
194 % 10 = 4
So 89809-65-4 is a valid CAS Registry Number.
InChI:InChI=1/C8H6N2O2/c1-12-8(11)6-2-3-7(4-9)10-5-6/h2-3,5H,1H3
89809-65-4Relevant articles and documents
Improving the Selectivity of PACE4 Inhibitors through Modifications of the P1 Residue
Dianati, Vahid,Navals, Pauline,Couture, Frédéric,Desjardins, Roxane,Dame, Anthony,Kwiatkowska, Anna,Day, Robert,Dory, Yves L.
, p. 11250 - 11260 (2019/01/04)
Paired basic amino acid cleaving enzyme 4 (PACE4), a serine endoprotease of the proprotein convertases family, has been recognized as a promising target for prostate cancer. We previously reported a selective and potent peptide-based inhibitor for PACE4, named the multi-Leu peptide (Ac-LLLLRVKR-NH2 sequence), which was then modified into a more potent and stable compound named C23 with the following structure: Ac-dLeu-LLLRVK-Amba (Amba: 4-amidinobenzylamide). Despite improvements in both in vitro and in vivo profiles of C23, its selectivity for PACE4 over furin was significantly reduced. We examined other Arg-mimetics instead of Amba to regain the lost selectivity. Our results indicated that the replacement of Amba with 5-(aminomethyl)picolinimidamide increased affinity for PACE4 and restored selectivity. Our results also provide a better insight on how structural differences between S1 pockets of PACE4 and furin could be employed in the rational design of selective inhibitors.
THERAPEUTIC AGENT FOR CEREBRAL INFARCTION
-
Page/Page column 20, (2010/03/04)
The present invention provides a novel therapeutic drug for cerebral infarction, which contains a piperazine compound as an active ingredient. The compound of the present invention can be provided as a novel therapeutic drug for cerebral infarction having
Substituted phenyl farnesyltransferase inhibitors
-
, (2012/09/25)
Compounds of formula (I) or pharmaceutically acceptable salts thereof, inhibit farnesyltransferase. Methods for making the compounds, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds are disclosed.